Citalopram
Product Images NDC 61919-390

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 61919-390). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Label)

This text contains information about different dosages and brands of the antidepressant drug Citalopram. The packages described contain 30 tablets of either 40mg or 10mg strength, with different expiry dates. The dosage instructions are not clearly visible. The text also mentions a generic version of the medication named "Generic for Celexa."*

FDA Label Image

Image Description (Molecule)

FDA Label Image

Image Description (Picture)

FDA Label Image

Image Description (Picture2)

FDA Label Image

Image Description (Table1 1)

FDA Label Image

Image Description (Table1)

The text describes a table showing the difference in the number of cases of suicidality per 1000 patients for different age ranges when taking a drug compared to a placebo. For patients under 18 years old, there were 14 additional cases of suicidality when taking the drug. For patients between 18 and 24 years old, there were 5 additional cases of suicidality when taking the drug. However, for patients between 25 and 64 years old, there were 6 fewer cases of suicidality when taking the drug compared to a placebo.*

FDA Label Image

Image Description (Table2 1)

This is a description of side effects of a medication or treatment. The text mentions that 3% of individuals using it experienced insomnia, 2% experienced somnolence (sleepiness), and there is a mention of agitation without any reported percentage.*

FDA Label Image

Image Description (Table2)

This text provides a table showing the percentage of patients discontinuing treatment due to adverse events in short-term, placebo-controlled, depression trials with citalopram and placebo. The adverse events are categorized by body system, and include asthenia, gastrointestinal disorders (nausea, dry mouth, vomiting), central and peripheral nervous system disorders (dizziness), and psychiatric disorders.*

FDA Label Image

Image Description (Table3 1)

This appears to be a list of reported side effects of a medication, categorized by body system. Some of the reported side effects include fatigue, fever, arthralgia (joint pain), myalgia (muscle pain), somnolence (drowsiness), insomnia, anxiety, anorexia (loss of appetite), agitation, dysmenorrhea (painful menstrual periods), decreased libido, yawning, upper respiratory tract infection, and sinusitis. The percentage values may represent the frequency of occurrence of these side effects in clinical trials or in post-marketing surveillance.*

FDA Label Image

Image Description (Table3 2)

This is a medical document listing urogenital disorders including ejaculation disorder and impotence. The percentage symbol may indicate a statistic or prevalence rate. However, due to the lack of context, it is not possible to provide more information.*

FDA Label Image

Image Description (Table3)

FDA Label Image

Image Description (Table4)

This text presents the side effects of the medication Citalopram on 425 male patients. The side effects include abnormal ejaculation (mostly ejaculatory delay), decreased libido, and impotence. The percentages of patients experiencing these side effects are given.*

FDA Label Image

Image Description (Table5 1)

This text is a list of two pharmaceutical compounds, hydrobromide and escitalopram oxalate, and their common trade name Lexapro.*

FDA Label Image

Image Description (Table5)

If you take citalopram tablets, you should not take any other medicines that contain citalopram.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.